ARTICLE | Company News
Apitope, Merck KGaA deal
October 24, 2016 7:00 AM UTC
Merck returned global rights to multiple sclerosis candidate ATX-MS-1467 to Apitope, terminating the partners’ 2009 deal. The vaccine containing four synthetic peptides derived from human myelin basic...